AssetMark’s Standard BioTools LAB Stock Holding History
Bought
Maintained
Sold
Other funds holding LAB
ICM
TM
AssetMark's LAB Position: Q1 2024 in Review
AssetMark sold out of Standard BioTools (LAB) in Q1 2024, closing a stake of 62 shares — an estimated $137 sold.
AssetMark first reported a position in LAB in Q3 2015 and held it in 3 quarters. The position peaked at $137 in Q4 2023. 146 funds tracked by Wall St. Rank hold LAB as of Q1 2024.
- AssetMark reported no remaining Standard BioTools position as of Q1 2024 after selling out during the quarter.
- AssetMark sold 62 Standard BioTools shares in Q1 2024, an estimated $137.
- AssetMark first reported a position in Standard BioTools in Q3 2015 and held it in 3 quarters.
- AssetMark's Standard BioTools position peaked at $137 in Q4 2023.
- 146 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2024.
Based on AssetMark's 13F filing for Q1 2024, filed 7 May 2024.